Lv2
124 积分 2025-02-10 加入
补充材料 Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
8小时前
待确认
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
9小时前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
9天前
已完结
Computed tomography-guided interstitial implantation of I (125) radioactive seeds in the treatment of hilar airway stenosis caused by non-small cell lung cancer
2个月前
已关闭
Features of post-obstructive pneumonia in advanced lung cancer patients, a large retrospective cohort
2个月前
已完结
Considerations in Kp,uu,brain-based Strategy for Selecting CNS-targeted Drug Candidates with Sufficient Target Coverage and Substantial Pharmacodynamic Effect
2个月前
已完结
Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors
4个月前
已完结
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma
4个月前
已完结
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer
4个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
4个月前
已完结
皖公网安备34019202002308
